At NETRF, our mission is to fund research that holds promise for advancing the understanding and treatment of neuroendocrine neoplasms (NENs). This is a commitment
Recent advancements have broadened the spectrum of treatments for advanced NETs, encompassing a range of therapies that include peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE.
Four NETRF-funded researchers were recognized for excellence and received awards at the recent European Neuroendocrine Tumor Society (ENETS) annual meeting in Vienna, Austria. CEO Elyse
The FDA has granted breakthrough therapy designation to AlphaMedixTM (212Pb-DOTAMTATE) for treating adults with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), marking it as the first targeted
In 2019, Claire Mulvey, MD, received a NETRF Mentored Research Award to study the trends in incidence and survival outcomes for lung NETs. The goal
The Neuroendocrine Tumor Research Foundation (NETRF) is pleased to announce its 2024 Request for Applications. We’re seeking transformative research proposals in basic, translational, and clinical
U.S. & International Scientists to focus on drug therapies, radiopharmaceuticals, and progression of NETs [BOSTON, MA, January 17, 2024–] The Neuroendocrine Tumor Research Foundation (NETRF)
Lung neuroendocrine tumors (NETs) are graded as typical or atypical carcinoids based on how quickly the tumor cells divide. They exhibit diverse clinical behaviors and
Midgut neuroendocrine tumors (NETs), such as small intestinal NETs, originate in the neuroendocrine cells of the midgut, a part of the digestive system, and have
As we reflect on the past year, the Neuroendocrine Tumor Research Foundation (NETRF) takes immense pride in the strides we have made towards understanding and